Genfit SA
Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fi… Read more
Market Cap & Net Worth: Genfit SA (GNFTF)
Genfit SA (PINK:GNFTF) has a market capitalization of $177.13 Million ($177.13 Million) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #16623 globally and #6369 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genfit SA's stock price $3.54 by its total outstanding shares 50036790 (50.04 Million).
Genfit SA Market Cap History: 2015 to 2025
Genfit SA's market capitalization history from 2015 to 2025. Data shows change from $1.69 Billion to $177.13 Million (-22.76% CAGR).
Genfit SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genfit SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.14x
Genfit SA's market cap is 4.14 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
184.28x
Genfit SA's market cap is 184.28 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.69 Billion | $527.00K | -$17.14 Million | 3214.55x | N/A |
| 2016 | $1.10 Billion | $284.00K | -$33.67 Million | 3876.09x | N/A |
| 2017 | $1.42 Billion | $118.00K | -$58.60 Million | 12073.28x | N/A |
| 2018 | $1.00 Billion | $69.00K | -$79.52 Million | 14503.42x | N/A |
| 2019 | $1.00 Billion | $30.84 Million | -$65.14 Million | 32.45x | N/A |
| 2020 | $242.68 Million | $765.00K | -$101.22 Million | 317.23x | N/A |
| 2021 | $250.18 Million | $80.07 Million | $67.26 Million | 3.12x | 3.72x |
| 2022 | $184.64 Million | $20.20 Million | -$23.72 Million | 9.14x | N/A |
| 2023 | $172.63 Million | $28.57 Million | -$28.89 Million | 6.04x | N/A |
| 2024 | $277.70 Million | $67.00 Million | $1.51 Million | 4.14x | 184.28x |
Competitor Companies of GNFTF by Market Capitalization
Companies near Genfit SA in the global market cap rankings as of March 19, 2026.
Key companies related to Genfit SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Genfit SA Historical Marketcap From 2015 to 2025
Between 2015 and today, Genfit SA's market cap moved from $1.69 Billion to $ 177.13 Million, with a yearly change of -22.76%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $177.13 Million | -36.22% |
| 2024 | $277.70 Million | +60.87% |
| 2023 | $172.63 Million | -6.50% |
| 2022 | $184.64 Million | -26.20% |
| 2021 | $250.18 Million | +3.09% |
| 2020 | $242.68 Million | -75.75% |
| 2019 | $1.00 Billion | 0.00% |
| 2018 | $1.00 Billion | -29.76% |
| 2017 | $1.42 Billion | +29.42% |
| 2016 | $1.10 Billion | -35.02% |
| 2015 | $1.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Genfit SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $177.13 Million USD |
| MoneyControl | $177.13 Million USD |
| MarketWatch | $177.13 Million USD |
| marketcap.company | $177.13 Million USD |
| Reuters | $177.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.